Phytoestrogenic treatment of vaginal atrophy in postmenopausal women

The effect of red clover vaginal cream on vaginal atrophy in postmenopausal women

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171224038036N2

Enrollment

Registered

2018-01-11

Start date

2018-02-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Atrophy. Postmenopausal atrophic vaginitis

Interventions

Intervention 1: Intervention group: Red clover vaginal cream 2% One application once a day for 8 weeks. Intervention 2: Control group: Placebo, vaginal cream, once a day for 8 weeks.

Treatment - Drugs

Placebo

Intervention group: Red clover vaginal cream 2% One application once a day for 8 weeks

Control group: Placebo, vaginal cream, once a day for 8 weeks

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age range from 45 to 65 years Women with at least one year of menstruation or having a hormonal test with an FSH level higher than 40 international units with a spouse Having sexual activity The presence of vaginal atrophy

Exclusion criteria

Exclusion criteria: Vaginal bleeding with unknown cause Vaginal infection Hormone therapy or use of sex hormones 8 weeks before study Taking isoflavones in the diet History of suspected breast mass or breast cancer Hospital admission during research Unwillingness to continue the study company

Design outcomes

Primary

Measure	Time frame
Vaginal atrophy. Timepoint: Before intervention, after intervention. Method of measurement: Vaginal smear.	—

Secondary

Measure	Time frame
Dyspareunia. Timepoint: Before the intervention, two weeks after the intervention, four weeks after the intervention, eight weeks after the intervention. Method of measurement: 4 degree self-rating scale.;Sexual performance. Timepoint: Before and after intervention. Method of measurement: Female Sexual Function Index (FSFI).;Sexual satisfaction. Timepoint: Before and after the intervention. Method of measurement: Larsson Sexual Satisfaction Questionnaire.;Severity of menopause symptoms. Timepoint: Before the intervention, two, four, and eight weeks after the intervention. Method of measurement: Menopause Rating Scale Questionnaire.	—

Measure

Time frame

Dyspareunia. Timepoint: Before the intervention, two weeks after the intervention, four weeks after the intervention, eight weeks after the intervention. Method of measurement: 4 degree self-rating scale.;Sexual performance. Timepoint: Before and after intervention. Method of measurement: Female Sexual Function Index (FSFI).;Sexual satisfaction. Timepoint: Before and after the intervention. Method of measurement: Larsson Sexual Satisfaction Questionnaire.;Severity of menopause symptoms. Timepoint: Before the intervention, two, four, and eight weeks after the intervention. Method of measurement: Menopause Rating Scale Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJamileh khayatan

Ahvaz University of Medical Sciences

Jamilehkhayatan@yahoo.com+98 61 3223 7134

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026